Adamantane derivs. for cyto-protection of cells - protects infected and non-infected lymphocytes and other cells, and can be used in treating e.g. AIDs and ARC

• Main Authors: BORMANN, JOACHIM, PRIV.-DOZ. DR., 3400 GOETTINGEN, DE, SCHATTON, WOLFGANG F. H.., 6236 ESCHBORN, DE, MUELLER, WERNER E. G., DR., 6200 WIESBADEN, DE
• Format: Patent
• Language: English; German
• Published: 14.11.1991
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

The use of adamantyl derivs. of formula (I) and their acid addn. salts, for the ctyo-protection of non-infected and virus-infected lymphocytes and other cell types is claimed. In (I) R1 to R5 = H or 1-4C opt. branched alkyl. (I) are known cpds. (DE2219256, DE2856393, US4122193 and DE2232735). USE/ADVANTAGE - (I) is used to treat disease where lymphocytes suffer cytopathic changes (claimed). Diseases causing such damage include HIV and human T cell leukaemia/lymphotropic virus type III. Treatment is for patients with HIV, AIDS, ARC and lymphadenopathy-associated virus (LAV) infections. The dose is 0.01-100 mg/kg, pref. in an oral dosage form which reaches the intestines. (I) may be administered simultaneously with other antiviral agents, e.g. 3'-azido-3'-desoxythymidine. In an example, the rate of incorporation of 3H-dThd in mouse lymphocytes was measured after 5 days treatment with memantine (1-amino-3,5-diemthyladamantane), followed by killing the mice and incubating the lymphocytes in foetal calf serum. 3H-dThd was added to the culture medium. In untreated animals, the rate of incorporation was 1.47, with 1 mg/kg it was 1.98, and with 10 mg/kg it was 4.84, in units of 1000 counts/minute/million cells.